← BOE Technology overview

BOE Technology vs Merck KGaA: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

BOE Technology Group Co Ltd (000725.CS)

Q3 2026
▲3▼1

BOE's AI pivot and OLED ramp drive Q3 gains, but panel price slump weighs

  • AI and Corning partnership BOE's AI-related glass substrate and optical interconnect technology, plus a substantive Corning partnership, attracted investor interest and positioned the company for growth in advanced display materials.

    This new strategic focus on AI and partnership with Corning was a key positive driver for the stock.

  • Record profit and OLED shipments Record first-half profit of 5.2 billion yuan (+61.6%) and OLED shipments exceeding 80 million units demonstrated strong operational performance and market traction.

    The strong financial results and shipment volumes directly boosted investor confidence.

  • Institutional interest and buybacks High institutional interest (238 visits), China's first 8.6-generation OLED line entering mass production, and buybacks plus a controlling-shareholder purchase plan signaled confidence and supported the share price.

    These actions and milestones reinforced positive sentiment and provided price support.

  • Falling OLED prices and unprofitable OLED business Flexible OLED panel prices continue falling—a 6.7-inch panel may drop to $18 in Q3 2026, down 50% from early 2023—due to weak phone demand and oversupply, and the chairman admits the OLED business remains unprofitable, pressuring earnings.

    This persistent price decline and lack of profitability pose a significant risk to future earnings.

August 2026
▲3▼1

BOE's Profit Surge and Buybacks Offset OLED Price Weakness

  • Record First-Half Profit and OLED Shipments BOE's first-half profit jumped 61.6% to 5.2 billion yuan, with OLED shipments exceeding 80 million units. This strong operational performance confirms the company's growth trajectory and boosts investor confidence.

    This is a key new financial result that directly supports the stock price.

  • Mass Production of China's First 8.6-Generation OLED Line China's first 8.6-generation OLED line entered mass production, enhancing BOE's production efficiency and scale. This milestone strengthens its competitive position in the global display market.

    This is a new operational milestone that improves future supply capacity and cost structure.

  • Shareholder Buybacks and Controlling Shareholder Purchase Plan The controlling shareholder plans to buy 500 million–1 billion yuan of stock, and BOE completed a 500 million yuan A-share buyback plus HK$393 million of B-shares. These actions signal confidence and support the share price.

    Buybacks and insider buying are direct capital actions that can lift the stock price.

  • Falling Flexible OLED Panel Prices and Unprofitable OLED Business Flexible OLED panel prices keep falling—a 6.7-inch panel may drop to $18 in Q3 2026, down 50% from early 2023—due to weak phone demand and oversupply. The chairman admits the OLED business remains unprofitable, pressuring earnings.

    This is a significant risk factor that could offset positive developments and weigh on the stock.

Latest
▲3▼1

BOE buybacks and glass-substrate push offset OLED price slump

  • BOE completes 500M yuan A-share buyback in half a month BOE repurchased 500 million yuan of A-shares by July 31, hitting the lower limit of its plan in about half a month, plus 393 million Hong Kong dollars of B-shares. Buybacks shrink the number of shares outstanding and signal management thinks the stock is cheap, supporting the price.

    This is a fresh, concrete capital action that directly reduces share count and signals confidence.

  • BOE prepares glass substrate line for AI chip packaging BOE is preparing to invest in a mass production line for semiconductor glass substrate carriers, and its 20-layer large-size sample passed six reliability tests and was sent to leading domestic AI chip makers. This opens a new high-value business beyond displays, which could lift future profits and the stock.

    It shows a new growth avenue in AI chip packaging that could re-rate the company beyond its display cycle.

  • Falling flexible OLED panel prices squeeze BOE's OLED profit Flexible OLED panel prices keep falling — a 6.7-inch panel is expected to drop to 18 US dollars in Q3 2026, down 50 percent from early 2023 — because phone demand is shrinking and supply is too high. BOE's chairman says the OLED business is very difficult and still not profitable, which pressures earnings and the stock.

    This is the main real counterweight: it explains why BOE's core OLED business is under margin pressure despite shipment growth.

  • BOE launches fourth-generation Oriental Screen on OnePlus 16 BOE and OnePlus launched the fourth-generation Oriental Screen, debuting on the OnePlus 16 flagship. It uses new luminescent materials, a 165Hz refresh rate and a 22-nanometer driver chip, with 10 percent more brightness and 15 percent less power. Winning flagship design slots supports premium pricing and shows BOE's technology lead.

    It demonstrates BOE's high-end product competitiveness, which can help offset the price decline in standard OLED panels.

▲4

BOE profit jumps, buybacks and state chip plan lift shares

  • Controlling shareholder to buy 500M–1B yuan of stock Beijing Electronics Holdings, BOE's controlling shareholder, plans to buy 500 million to 1 billion yuan of BOE A-shares. Big owners buying signals confidence and adds real demand for the stock, supporting the price.

    New capital action by the controlling shareholder directly supports the share price.

  • First-half profit up 61.6% to 5.2 billion yuan BOE's first-half 2026 revenue topped 103.1 billion yuan and net profit rose 61.6% to 5.2 billion yuan. Stronger earnings show the display business is making more money, which supports a higher stock price.

    The profit surge is the core fundamental driver of the stock's value.

  • OLED shipments top 80 million, 8.6-gen line starts mass production BOE shipped over 80 million OLED units in the first half, ranking first in China and second globally, and China's first 8.6-generation OLED line began mass production in June. This expands high-value output and future revenue.

    New production capacity and shipment leadership drive future earnings growth.

  • China's five-year plan names consumer electronics a priority China's 15th five-year plan for electronics (2026–2030) names consumer electronics and basic electronics as priority industries, sending BOE shares up 2.1%. Expected state support improves the outlook for demand and investment in the sector.

    New government policy directly benefits BOE's core business and investor sentiment.

July 2026
▲3

BOE Surges on Glass Substrate Tech and Strong Profit Outlook

  • Institutional Buying and Glass Substrate Focus BOE attracted 238 institutional visits, the most of any stock, with focus on its glass substrate and optical interconnect technology. This signals strong professional investor confidence, pushing the stock price up as demand for AI-related components grows.

    This is a new event that directly boosts investor sentiment and highlights BOE's technological edge.

  • Corning Partnership Advances BOE's collaboration with Corning has entered a substantive phase, targeting breakthroughs in glass-based packaging substrates, optical interconnects, perovskites, and foldable glass. This partnership could accelerate commercialization and open new revenue streams, driving the stock higher.

    It reveals a concrete partnership that enhances BOE's growth prospects in advanced materials.

  • Strong First-Half Profit Forecast BOE expects first-half net profit of 5–5.5 billion yuan, up 54–69% year-on-year. This robust earnings growth confirms improving profitability and supports a higher stock price as investors anticipate continued strong performance.

    It provides concrete financial guidance that directly impacts valuation and investor confidence.

▲3

BOE Surges on Glass Substrate Tech and Strong Profit Outlook

  • Institutional Buying and Glass Substrate Focus BOE attracted 238 institutional visits, the most of any stock, with focus on its glass substrate and optical interconnect technology. This signals strong professional investor confidence, pushing the stock price up as demand for AI-related components grows.

    This is a new event that directly boosts investor sentiment and highlights BOE's technological edge.

  • Corning Partnership Advances BOE's collaboration with Corning has entered a substantive phase, targeting breakthroughs in glass-based packaging substrates, optical interconnects, perovskites, and foldable glass. This partnership could accelerate commercialization and open new revenue streams, driving the stock higher.

    It reveals a concrete partnership that enhances BOE's growth prospects in advanced materials.

  • Strong First-Half Profit Forecast BOE expects first-half net profit of 5–5.5 billion yuan, up 54–69% year-on-year. This robust earnings growth confirms improving profitability and supports a higher stock price as investors anticipate continued strong performance.

    It provides concrete financial guidance that directly impacts valuation and investor confidence.

Merck KGaA (MRK.XETRA)

Q3 2026
▲2▼1

Merck KGaA advances Bio-Techne deal, raises guidance, but faces German rebate and Healthcare headwinds

  • Guidance raised on strong Q2 results Merck KGaA increased its 2026 outlook after Q2 organic sales grew 4.1% and EBITDA pre rose 9.3%, driven by Life Science and Electronics. This signaled confidence in continued momentum.

    The guidance raise reflects better-than-expected performance and is a new positive development this quarter.

  • Pipeline and regulatory wins The company achieved FDA Breakthrough status for lupus drug enpatoran, updated the European Erbitux label, made fertility acquisitions, and reported positive remigromig trial results. UBS also named Merck a favoured patent-light compounder.

    These pipeline and regulatory milestones are new positive catalysts that support future growth.

  • German rebate hike and Healthcare decline Germany's healthcare reform raised mandatory drug rebates, which Merck warned harms investment and innovation. Meanwhile, Healthcare fell 3.4% due to U.S. competition and Mavenclad's patent loss.

    This is a new negative factor that pressured the Healthcare segment and overall sentiment.

August 2026
▲4

Merck KGaA raises outlook, buys Bio-Techne, and posts drug wins

  • Raised 2026 guidance on Life Science and Electronics strength Merck lifted its full-year 2026 outlook after Q2 organic sales rose 4.1% and EBITDA pre climbed 9.3% to 1.6 billion euros. Life Science and Electronics (AI/data-center chips) led; Healthcare fell 3.4% on U.S. competition and Mavenclad patent loss. Higher profit expectations support the share price.

    Guidance raise is the core earnings driver behind the stock's re-rating this period.

  • Bio-Techne takeover clears key hurdles toward $11.3 billion deal Bio-Techne shareholders approved Merck's $73-a-share cash buyout, and the U.S. antitrust waiting period expired. The deal, worth about $11.3 billion including debt, is expected to close late 2026 or early 2027 with roughly 140 million euros of annual cost savings. It expands Merck's life-science tools business.

    The acquisition is a major capital move that reshapes Merck's Life Science portfolio and is now near closing.

  • Pipeline progress: fertility drugs acquired and eye-disease drug succeeds EMD Serono bought PostEra's two preclinical fertility programs, adding oral alternatives to IVF injections. Separately, remigromig met the main goal in the pivotal BRUNELLO trial for diabetic macular edema, though it showed more eye side effects than the control. Both strengthen the healthcare pipeline.

    New drug assets and a pivotal trial win are the main healthcare growth catalysts this period.

  • Electronics and screening markets expand, with new Japan investment Merck plans to invest over 70 million euros in an advanced semiconductor materials center in Japan, betting on chip demand. A separate report projects the high-throughput screening market to grow 10.7% a year to $45.9 billion by 2031, with Merck among key players. Both support its Electronics and Life Science units.

    These show structural demand growth in two of Merck's three core businesses.

Latest
▲4

Merck KGaA raises outlook, buys Bio-Techne, and posts drug wins

  • Raised 2026 guidance on Life Science and Electronics strength Merck lifted its full-year 2026 outlook after Q2 organic sales rose 4.1% and EBITDA pre climbed 9.3% to 1.6 billion euros. Life Science and Electronics (AI/data-center chips) led; Healthcare fell 3.4% on U.S. competition and Mavenclad patent loss. Higher profit expectations support the share price.

    Guidance raise is the core earnings driver behind the stock's re-rating this period.

  • Bio-Techne takeover clears key hurdles toward $11.3 billion deal Bio-Techne shareholders approved Merck's $73-a-share cash buyout, and the U.S. antitrust waiting period expired. The deal, worth about $11.3 billion including debt, is expected to close late 2026 or early 2027 with roughly 140 million euros of annual cost savings. It expands Merck's life-science tools business.

    The acquisition is a major capital move that reshapes Merck's Life Science portfolio and is now near closing.

  • Pipeline progress: fertility drugs acquired and eye-disease drug succeeds EMD Serono bought PostEra's two preclinical fertility programs, adding oral alternatives to IVF injections. Separately, remigromig met the main goal in the pivotal BRUNELLO trial for diabetic macular edema, though it showed more eye side effects than the control. Both strengthen the healthcare pipeline.

    New drug assets and a pivotal trial win are the main healthcare growth catalysts this period.

  • Electronics and screening markets expand, with new Japan investment Merck plans to invest over 70 million euros in an advanced semiconductor materials center in Japan, betting on chip demand. A separate report projects the high-throughput screening market to grow 10.7% a year to $45.9 billion by 2031, with Merck among key players. Both support its Electronics and Life Science units.

    These show structural demand growth in two of Merck's three core businesses.

July 2026
▲3▼1

Merck KGaA expands life-science and pipeline while German drug rebates bite

  • Bio-Techne acquisition at 36% premium Merck KGaA agreed to buy Bio-Techne for $73 per share in cash, an $11.3 billion deal at a 36% premium. Buying a profitable life-science tools maker expands Merck's lab-supplies business and signals confidence, which supports the share price.

    This is the largest new deal and a direct driver of Merck KGaA's valuation.

  • UBS backs Merck KGaA as patent-light compounder UBS reiterated an overweight stance on European pharma and named Merck KGaA a favoured patent-light compounder, citing improving earnings and low valuations. More investor money flowing into the sector and into Merck specifically can lift the share price.

    Analyst positioning directly influences demand for the stock.

  • German healthcare reform raises pharma rebates Germany's Bundestag passed a reform cutting health costs by over €16 billion, raising mandatory rebates drugmakers pay. Merck KGaA warned this harms investment and innovation, a real headwind to future earnings and a counterweight to the positive news.

    This is the main negative force on Merck KGaA's home-market profitability.

  • Pipeline wins and AI partnership cut costs Merck KGaA's lupus drug enpatoran won FDA Breakthrough Therapy status, Erbitux got a European label update, and a multi-year AI deal with Evinova aims to speed trials and cut costs. These advances support future revenue and efficiency.

    Pipeline and technology progress are core to Merck KGaA's long-term growth story.

▲3▼1

Merck KGaA expands life-science and pipeline while German drug rebates bite

  • Bio-Techne acquisition at 36% premium Merck KGaA agreed to buy Bio-Techne for $73 per share in cash, an $11.3 billion deal at a 36% premium. Buying a profitable life-science tools maker expands Merck's lab-supplies business and signals confidence, which supports the share price.

    This is the largest new deal and a direct driver of Merck KGaA's valuation.

  • UBS backs Merck KGaA as patent-light compounder UBS reiterated an overweight stance on European pharma and named Merck KGaA a favoured patent-light compounder, citing improving earnings and low valuations. More investor money flowing into the sector and into Merck specifically can lift the share price.

    Analyst positioning directly influences demand for the stock.

  • German healthcare reform raises pharma rebates Germany's Bundestag passed a reform cutting health costs by over €16 billion, raising mandatory rebates drugmakers pay. Merck KGaA warned this harms investment and innovation, a real headwind to future earnings and a counterweight to the positive news.

    This is the main negative force on Merck KGaA's home-market profitability.

  • Pipeline wins and AI partnership cut costs Merck KGaA's lupus drug enpatoran won FDA Breakthrough Therapy status, Erbitux got a European label update, and a multi-year AI deal with Evinova aims to speed trials and cut costs. These advances support future revenue and efficiency.

    Pipeline and technology progress are core to Merck KGaA's long-term growth story.

Q2 2026
▲3

Merck KGaA Buys Bio-Techne for $11.3B, Launches Gene Therapy Venture

  • Bio-Techne Acquisition Merck KGaA agreed to buy Bio-Techne for $11.3 billion, its largest deal since 2015. The $73 per share cash offer is a 36% premium. The deal is expected to immediately boost profitability with €140 million in annual cost savings. Shares jumped 5.3% on the news.

    This is the biggest new event driving the stock, directly boosting Merck's life sciences business and investor confidence.

  • Saturnus Bio Collaboration Merck KGaA invested $50 million upfront in Saturnus Bio, a biotech developing gene therapies for rare heart diseases. Merck gets exclusive rights to acquire Saturnus later. This adds a new technology platform and pipeline option in precision cardiology.

    This new partnership shows Merck's push into high-growth gene therapy, supporting future revenue potential.

  • Keytruda EU Approval Merck KGaA received European Commission approval for Keytruda combined with Padcev as a neoadjuvant treatment for muscle-invasive bladder cancer. This expands the label for a key cancer drug, potentially increasing sales in Europe.

    A new regulatory approval for a major drug adds to Merck's oncology revenue stream.

June 2026
▲3

Merck KGaA Buys Bio-Techne for $11.3B, Launches Gene Therapy Venture

  • Bio-Techne Acquisition Merck KGaA agreed to buy Bio-Techne for $11.3 billion, its largest deal since 2015. The $73 per share cash offer is a 36% premium. The deal is expected to immediately boost profitability with €140 million in annual cost savings. Shares jumped 5.3% on the news.

    This is the biggest new event driving the stock, directly boosting Merck's life sciences business and investor confidence.

  • Saturnus Bio Collaboration Merck KGaA invested $50 million upfront in Saturnus Bio, a biotech developing gene therapies for rare heart diseases. Merck gets exclusive rights to acquire Saturnus later. This adds a new technology platform and pipeline option in precision cardiology.

    This new partnership shows Merck's push into high-growth gene therapy, supporting future revenue potential.

  • Keytruda EU Approval Merck KGaA received European Commission approval for Keytruda combined with Padcev as a neoadjuvant treatment for muscle-invasive bladder cancer. This expands the label for a key cancer drug, potentially increasing sales in Europe.

    A new regulatory approval for a major drug adds to Merck's oncology revenue stream.

▲3

Merck KGaA Buys Bio-Techne for $11.3B, Launches Gene Therapy Venture

  • Bio-Techne Acquisition Merck KGaA agreed to buy Bio-Techne for $11.3 billion, its largest deal since 2015. The $73 per share cash offer is a 36% premium. The deal is expected to immediately boost profitability with €140 million in annual cost savings. Shares jumped 5.3% on the news.

    This is the biggest new event driving the stock, directly boosting Merck's life sciences business and investor confidence.

  • Saturnus Bio Collaboration Merck KGaA invested $50 million upfront in Saturnus Bio, a biotech developing gene therapies for rare heart diseases. Merck gets exclusive rights to acquire Saturnus later. This adds a new technology platform and pipeline option in precision cardiology.

    This new partnership shows Merck's push into high-growth gene therapy, supporting future revenue potential.

  • Keytruda EU Approval Merck KGaA received European Commission approval for Keytruda combined with Padcev as a neoadjuvant treatment for muscle-invasive bladder cancer. This expands the label for a key cancer drug, potentially increasing sales in Europe.

    A new regulatory approval for a major drug adds to Merck's oncology revenue stream.